Clinical support protocol for SS-31 under physician supervision.
SS-31 is part of the Mital clinical catalog as a peptide-focused entry with standardized preparation, dosing, and quality-control guidance.
Mechanism of Action - Performance & Endurance Pathway
Use physician-guided initiation, titration, and maintenance phases aligned with response, tolerability, and objective biomarkers.
| Period | Dose | Phase | Clinical Notes |
|---|---|---|---|
| Weeks 1-2 | Initial phase | initiation | Begin conservatively and monitor tolerance. |
| Weeks 3-6 | Escalation phase | escalation | Increase per protocol if tolerated. |
| Week 7+ | Maintenance phase | maintenance | Maintain target dose and reassess monthly. |
Reconstitute with bacteriostatic water using aseptic handling. Inject diluent slowly along the vial wall and swirl gently until fully dissolved.
No reconstitution guide available for this strength.
Identity
- Product Name: SS-31
- Strength Options: 50 mg
Quality & Purity
- Purity: >= 99%
- Sterility: Aseptic handling required
Storage & Handling
- Storage: 2-8 C refrigerated
- Handling: Avoid heat, shaking, and direct light
Timing: Use consistent administration timing for stable protocol tracking.
Storage: Store refrigerated at 2-8 C and protect from heat and light.
Frequency: Frequency follows protocol phase and physician direction.
Cycle: Cycle length and cadence are clinician-defined per patient profile.
Injection Sites: Rotate approved injection sites to reduce local irritation risk.